NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor

Elena Galvani(Amsterdam UMC Location VUmc), Elisa Giovannetti(University of Pisa)

Oncotarget

April 29, 2015

10.18632/oncotarget.3956

Cited by 31

Related Papers

Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer

|Journal of Hematology & Oncology|2017|84

Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells

|Cancers|2019|76

Prognostic Significance of Integrin Subunit Alpha 2 (ITGA2) and Role of Mechanical Cues in Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma (PDAC)

|Cancers|2023|31

Biodegradable Ultrasmall-in-Nano Architectures Loaded with Cisplatin Prodrug in Combination with Ionizing Radiation Induces DNA Damage and Apoptosis in Pancreatic Ductal Adenocarcinoma

|Cancers|2022|21

5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer

|Oncotarget|2018|16